Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide pandemic, and there is a pressing need to understand the development, specificity, and neutralizing potency of humoral immune responses during acute infection. We report a cross-sectional study of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in a cohort of 44 hospitalized COVID-19 patients. RBD-specific IgG responses are detectable in all patients 6 days after PCR confirmation. Isotype switching to IgG occurs rapidly, primarily to IgG1 and IgG3. Using a clinical SARS-CoV-2 isolate, neutralizing antibody titers are detectable in all patients by 6 days after PCR confirmation and correlate with RBD-specific binding IgG titers. The RBD-specific binding data were further validated in a clinical setting with 231 PCR-confirmed COVID-19 patient samples. These findings have implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of much-needed vaccines.

Citing Articles

Serological response to lumpy skin disease in recovered and clinically healthy vaccinated and unvaccinated cattle of Bangladesh.

Parvin R, Al Mim S, Haque M, Jerin I, Nooruzzaman M, Hossain M Front Vet Sci. 2025; 12:1535600.

PMID: 40034563 PMC: 11873106. DOI: 10.3389/fvets.2025.1535600.

Longitudinal Surveillance of COVID-19 Antibodies in Pediatric Healthcare Workers.

Hatabah D, Gupta S, Mantus G, Sullivan P, Heilman S, Camacho-Gonzalez A Vaccines (Basel). 2025; 13(2).

PMID: 40006710 PMC: 11861628. DOI: 10.3390/vaccines13020163.

Longevity of antibody responses is associated with distinct antigen-specific B cell subsets early after infection.

Kuijper L, Kreher C, Elias G, Claireaux M, Kerster G, Bos A Front Immunol. 2025; 15:1505719.

PMID: 39742271 PMC: 11686410. DOI: 10.3389/fimmu.2024.1505719.

Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron.

Pinto P, Timis J, Chuensirikulchai K, Li Q, Lu H, Maule E NPJ Vaccines. 2024; 9(1):252.

PMID: 39702529 PMC: 11659323. DOI: 10.1038/s41541-024-01043-3.

Absolute concentration estimation of COVID-19 convalescent and post-vaccination IgG antibodies.

Klegerman M, Peng T, Seferovich I, Rahbar M, Hessabi M, Tahanan A PLoS One. 2024; 19(11):e0311777.

PMID: 39485748 PMC: 11530011. DOI: 10.1371/journal.pone.0311777.

References

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. PMC: 7259988. DOI: 10.1172/JCI138745. View

Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y . Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013; 500(7461):227-31. PMC: 7095341. DOI: 10.1038/nature12328. View

Buchholz U, Bukreyev A, Yang L, Lamirande E, Murphy B, Subbarao K . Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A. 2004; 101(26):9804-9. PMC: 470755. DOI: 10.1073/pnas.0403492101. View

Ter Meulen J, van den Brink E, Poon L, Marissen W, Leung C, Cox F . Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006; 3(7):e237. PMC: 1483912. DOI: 10.1371/journal.pmed.0030237. View

Bolles M, Donaldson E, Baric R . SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission. Curr Opin Virol. 2011; 1(6):624-34. PMC: 3237677. DOI: 10.1016/j.coviro.2011.10.012. View

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J . Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16):1582-1589. PMC: 7101507. DOI: 10.1001/jama.2020.4783. View

Tortorici M, Veesler D . Structural insights into coronavirus entry. Adv Virus Res. 2019; 105:93-116. PMC: 7112261. DOI: 10.1016/bs.aivir.2019.08.002. View

Li F, Li W, Farzan M, Harrison S . Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005; 309(5742):1864-8. DOI: 10.1126/science.1116480. View

10.

Rockx B, Corti D, Donaldson E, Sheahan T, Stadler K, Lanzavecchia A . Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol. 2008; 82(7):3220-35. PMC: 2268459. DOI: 10.1128/JVI.02377-07. View

11.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

12.

Bosch B, van der Zee R, de Haan C, Rottier P . The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003; 77(16):8801-11. PMC: 167208. DOI: 10.1128/jvi.77.16.8801-8811.2003. View

13.

Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D . Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2):281-292.e6. PMC: 7102599. DOI: 10.1016/j.cell.2020.02.058. View

14.

Liu W, Fontanet A, Zhang P, Zhan L, Xin Z, Baril L . Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006; 193(6):792-5. PMC: 7109932. DOI: 10.1086/500469. View

15.

Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel S, Murray J . Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States. Emerg Infect Dis. 2020; 26(6):1266-1273. PMC: 7258473. DOI: 10.3201/eid2606.200516. View

16.

Deming D, Sheahan T, Heise M, Yount B, Davis N, Sims A . Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 2006; 3(12):e525. PMC: 1716185. DOI: 10.1371/journal.pmed.0030525. View

17.

Smith K, Garman L, Wrammert J, Zheng N, Capra J, Ahmed R . Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc. 2009; 4(3):372-84. PMC: 2750034. DOI: 10.1038/nprot.2009.3. View

18.

Lee Y, Liao C, Liu P, Cheng C, Chung M, Liu C . Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients. J Infect. 2020; 81(2):e55-e58. PMC: 7177139. DOI: 10.1016/j.jinf.2020.04.019. View

19.

Okba N, Muller M, Li W, Wang C, GeurtsvanKessel C, Corman V . Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020; 26(7):1478-1488. PMC: 7323511. DOI: 10.3201/eid2607.200841. View

20.

Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z . Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020; 181(4):894-904.e9. PMC: 7144619. DOI: 10.1016/j.cell.2020.03.045. View